CBIO - タ―ガセプト （Catalyst Biosciences Inc. ） タ―ガセプトCBIOのチャート
CBIOの企業情報
| symbol | CBIO |
|---|---|
| 会社名 | Catalyst Biosciences Inc （タ―ガセプト） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 カタリスト・バイオサイエンシズ（Catalyst Biosciences Inc.）(旧名：Targacept Inc.)は臨床段階のバイオ医薬品会社である。同社は、重篤な疾患に対処する医薬品の作成・開発に焦点を当てる。同社は、血友病及び外科出血の治療を含む止血、及び腎臓移植における移植後腎機能発現遅延の予防及び視覚障害や失明を引き起こす可能性がある萎縮型加齢黄斑変性症の治療を含む炎症等の分野を中心として製品開発に取り組む。同社の止血製品候補は、CB 813d/PF-0520602、CB 2679d/ISU 304とFXaを含む。同社の炎症開発候補は、CB2782及び眼科を含む。同社の技術は、移植後腎機能発現遅延（DGF）のためのCB 2782、及び萎縮型加齢黄斑変性症（萎縮型AMD）プログラムにおけるリードを含む抗C3プロテアーゼを選択する。 タ―ガセプトは米国の神経系疾患と消化器疾患の治療薬に焦点を置くバイオ医薬品会社。ニコチン性ニュ―ロン受容体をタ―ゲットにした治療薬「NNRセラピュ―ティクス」の開発を行い、糖尿病性胃不全麻痺、統合失調症、アルツハイマ―病、注意欠陥多動性障害の治療薬として治験を行う。 Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including MarzAA, a subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. Its complement pipeline includes a pre-clinical C3-degrader program partnered with Biogen for dry age-related macular degeneration, an improved complement factor I protease for SQ replacement therapy in patients with CFI deficiency and C4b-degraders designed to target disorders of the classical complement pathway as well as other complement programs in development. |
| 本社所在地 | 260 Littlefield Ave. South San Francisco NC 94080 USA |
| 代表者氏名 | Augustine J. Lawlor アウグスティヌス・J・ローラー |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 650-745-0655 |
| 設立年月日 | 35490 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 19人 |
| url | www.catalystbiosciences.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cbio |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -25.34800 |
| 終値（lastsale） | 10.24 |
| 時価総額（marketcap） | 122293544.96 |
| 時価総額 | 時価総額（百万ドル） 113.33650 |
| 売上高 | 売上高（百万ドル） 0.64200 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -22.80950 |
| 当期純利益 | 当期純利益（百万ドル） -23.07000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Catalyst Biosciences Inc revenues decreased 98% to $6K. Net loss applicable to common stockholders decreased 17% to $11.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$7.10 to -$1.10. |
CBIOのテクニカル分析
CBIOのニュース
SHAREHOLDER ALERT: Weiss Law Reminds CBIO, TA, AQUA, and USX Shareholders About Its Ongoing Investigations 2023/04/13 12:00:00 Kwhen Finance
Griping stocks: Aytu BioPharma, Inc. (NASDAQ:AYTU 1.76%), Catalyst Biosciences, Inc. (NASDAQ:CBIO -2.83%) 2023/03/06 12:40:52 Stock Equity
AYTU has seen its SMA50 which is now -23.34%. In looking the SMA 200 we see that the stock has seen a -56.74%. CBIO has seen its SMA50 which is … The post Griping stocks: Aytu BioPharma, Inc. (NASDAQ:AYTU 1.76%), Catalyst Biosciences, Inc. (NASDAQ:CBIO -2.83%) appeared first on Stocks Equity .
Do you want to know where to find good stock? Take a look at Catalyst Biosciences Inc.’s (NASDAQ:CBIO) Sentiment Analysis 2023/02/28 17:16:00 US Post News
Catalyst Biosciences Inc. (CBIO)’s stock has witnessed a price hike of 27.46% from the previous close with its current price standing at $0.31. Its current price is -23.98% under its 52-week high of $0.40 and 436.90% more than its 52-week low of $0.06. Based on the past 30-day period, the stock price is -15.42% below […]
GC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in Hematology 2023/02/28 00:53:00 PR Newswire Asia (English)
Entered into an acquisition deal of 3 programs YONGIN, South Korea , Feb. 28, 2023 /PRNewswire/ -- GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products in South Korea , announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ : CBIO) to acquire 3 programs related to the orphan hematology disorders. This agreement will bring to GC Biopharma 3 programs, including "Marzeptacog alfa (MarzAA)", an engineered factor VIIa which is ready for Phase 3 clinical stage development. In its previous clinical development trials, "MarzAA" demonstrated efficacy and safety as a treatment for rare bleeding disorders. More significantly, "MarzAA", unlike majority of existing therapeutics, is delivered by subcutaneous injection, making it more convenient to administer and less burdensome for the patients, who require life-long treatment. It is GC Biopharma''s plan to continue development of the asset in pursuit of launching a first-in-class novel drug that will pave the way for the company to make inroads into the global markets, including the US and other advanced markets.
With 79.31% From The Low, Is Catalyst Biosciences Inc. (NASDAQ:CBIO) Up For More Gains? 2023/01/28 18:00:00 Marketing Sentinel
In last trading session, Catalyst Biosciences Inc. (NASDAQ:CBIO) saw 0.57 million shares changing hands with its beta currently measuring 0.93. Company’s recent per share price level of $0.29 trading at -$0.01 or -2.99% at ring of the bell on the day assigns it a market valuation of $10.39M. That closing price of CBIO’s stock is … With 79.31% From The Low, Is Catalyst Biosciences Inc. (NASDAQ:CBIO) Up For More Gains? Read More »
SHAREHOLDER ALERT: Weiss Law Reminds CBIO, TA, AQUA, and USX Shareholders About Its Ongoing Investigations 2023/04/13 12:00:00 Kwhen Finance
Griping stocks: Aytu BioPharma, Inc. (NASDAQ:AYTU 1.76%), Catalyst Biosciences, Inc. (NASDAQ:CBIO -2.83%) 2023/03/06 12:40:52 Stock Equity
AYTU has seen its SMA50 which is now -23.34%. In looking the SMA 200 we see that the stock has seen a -56.74%. CBIO has seen its SMA50 which is … The post Griping stocks: Aytu BioPharma, Inc. (NASDAQ:AYTU 1.76%), Catalyst Biosciences, Inc. (NASDAQ:CBIO -2.83%) appeared first on Stocks Equity .
Do you want to know where to find good stock? Take a look at Catalyst Biosciences Inc.’s (NASDAQ:CBIO) Sentiment Analysis 2023/02/28 17:16:00 US Post News
Catalyst Biosciences Inc. (CBIO)’s stock has witnessed a price hike of 27.46% from the previous close with its current price standing at $0.31. Its current price is -23.98% under its 52-week high of $0.40 and 436.90% more than its 52-week low of $0.06. Based on the past 30-day period, the stock price is -15.42% below […]
GC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in Hematology 2023/02/28 00:53:00 PR Newswire Asia (English)
Entered into an acquisition deal of 3 programs YONGIN, South Korea , Feb. 28, 2023 /PRNewswire/ -- GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products in South Korea , announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ : CBIO) to acquire 3 programs related to the orphan hematology disorders. This agreement will bring to GC Biopharma 3 programs, including "Marzeptacog alfa (MarzAA)", an engineered factor VIIa which is ready for Phase 3 clinical stage development. In its previous clinical development trials, "MarzAA" demonstrated efficacy and safety as a treatment for rare bleeding disorders. More significantly, "MarzAA", unlike majority of existing therapeutics, is delivered by subcutaneous injection, making it more convenient to administer and less burdensome for the patients, who require life-long treatment. It is GC Biopharma''s plan to continue development of the asset in pursuit of launching a first-in-class novel drug that will pave the way for the company to make inroads into the global markets, including the US and other advanced markets.
With 79.31% From The Low, Is Catalyst Biosciences Inc. (NASDAQ:CBIO) Up For More Gains? 2023/01/28 18:00:00 Marketing Sentinel
In last trading session, Catalyst Biosciences Inc. (NASDAQ:CBIO) saw 0.57 million shares changing hands with its beta currently measuring 0.93. Company’s recent per share price level of $0.29 trading at -$0.01 or -2.99% at ring of the bell on the day assigns it a market valuation of $10.39M. That closing price of CBIO’s stock is … With 79.31% From The Low, Is Catalyst Biosciences Inc. (NASDAQ:CBIO) Up For More Gains? Read More »
Griping stocks: Aytu BioPharma, Inc. (NASDAQ:AYTU 1.76%), Catalyst Biosciences, Inc. (NASDAQ:CBIO -2.83%) 2023/03/06 12:40:52 Stock Equity
AYTU has seen its SMA50 which is now -23.34%. In looking the SMA 200 we see that the stock has seen a -56.74%. CBIO has seen its SMA50 which is … The post Griping stocks: Aytu BioPharma, Inc. (NASDAQ:AYTU 1.76%), Catalyst Biosciences, Inc. (NASDAQ:CBIO -2.83%) appeared first on Stocks Equity .
Do you want to know where to find good stock? Take a look at Catalyst Biosciences Inc.’s (NASDAQ:CBIO) Sentiment Analysis 2023/02/28 17:16:00 US Post News
Catalyst Biosciences Inc. (CBIO)’s stock has witnessed a price hike of 27.46% from the previous close with its current price standing at $0.31. Its current price is -23.98% under its 52-week high of $0.40 and 436.90% more than its 52-week low of $0.06. Based on the past 30-day period, the stock price is -15.42% below […]
GC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in Hematology 2023/02/28 00:53:00 PR Newswire Asia (English)
Entered into an acquisition deal of 3 programs YONGIN, South Korea , Feb. 28, 2023 /PRNewswire/ -- GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products in South Korea , announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ : CBIO) to acquire 3 programs related to the orphan hematology disorders. This agreement will bring to GC Biopharma 3 programs, including "Marzeptacog alfa (MarzAA)", an engineered factor VIIa which is ready for Phase 3 clinical stage development. In its previous clinical development trials, "MarzAA" demonstrated efficacy and safety as a treatment for rare bleeding disorders. More significantly, "MarzAA", unlike majority of existing therapeutics, is delivered by subcutaneous injection, making it more convenient to administer and less burdensome for the patients, who require life-long treatment. It is GC Biopharma''s plan to continue development of the asset in pursuit of launching a first-in-class novel drug that will pave the way for the company to make inroads into the global markets, including the US and other advanced markets.
With 79.31% From The Low, Is Catalyst Biosciences Inc. (NASDAQ:CBIO) Up For More Gains? 2023/01/28 18:00:00 Marketing Sentinel
In last trading session, Catalyst Biosciences Inc. (NASDAQ:CBIO) saw 0.57 million shares changing hands with its beta currently measuring 0.93. Company’s recent per share price level of $0.29 trading at -$0.01 or -2.99% at ring of the bell on the day assigns it a market valuation of $10.39M. That closing price of CBIO’s stock is … With 79.31% From The Low, Is Catalyst Biosciences Inc. (NASDAQ:CBIO) Up For More Gains? Read More »
This stocks will Fire Up Your investment: Intelligent Bio Solutions Inc. (NASDAQ:INBS -9.24%), Catalyst Biosciences, Inc. (NASDAQ:CBIO 7.07%) 2023/01/25 17:24:33 Stock Equity
INBS has seen its SMA50 which is now 210.42%. In looking the SMA 200 we see that the stock has seen a 95.88%. CBIO has seen its SMA50 which is … The post This stocks will Fire Up Your investment: Intelligent Bio Solutions Inc. (NASDAQ:INBS -9.24%), Catalyst Biosciences, Inc. (NASDAQ:CBIO 7.07%) appeared first on Stocks Equity .